Table 1.
The antibody target in CSC through different mechanisms in different tumors.
| Antigen | Targeting mechanism | Inhibitor | Cancer tested | References |
|---|---|---|---|---|
| CD44 | marker | H90 | AML | (142, 143) |
| CD133 | marker | Oxyteracycline FIBPi |
Liver Colon |
(144, 145) |
| CD20 | Marker | Rituximab | Lymphoma | (146) |
| EGFR | Marker | Ectuximab | Head and neck Squamous cell Breast Esophagus |
(147–149) |
| ABC transporters | Erlotinib Lapatinib Imatibib Nilotinib |
Under test | (151) | |
| targomiRs | EGFR | Clincal phase 1 | Malignant pleural mesothelioma Lung |
(156) |
| TRAIL | Apoptosis | JNKi | pancreas | (158) |
| NF-κB | Apoptosis | MG132 | leukemic | (159) |